Quantification of regional glial fibrillary acidic protein levels in Alzheimer's disease

Acta Neurol Scand. 2003 May;107(5):318-23. doi: 10.1034/j.1600-0404.2003.02098.x.


Objectives: Our objectives were to quantify glial fibrillary acidic protein (GFAP) in brains of Alzheimer's disease (AD) cases, and non-AD controls to determine the regions with the most severe gliosis in AD.

Material and methods: In a case control design, we used an enzyme-linked immunosorbent assay (ELISA) to quantify GFAP in frozen brain from four areas of neocortex in 10 AD cases, 10 age-matched controls, and 10 younger controls from the Honolulu-Asia Aging Study autopsy archive.

Results: Median age at death was 83.5 years for cases and age-matched controls, and 77 years for younger controls. For the AD cases compared with the age-matched controls, levels of GFAP in occipital (P=0.01), parietal (P=0.028), and temporal lobes (P=0.004) (but not frontal) were significantly higher in the cases. The median GFAP excess in AD cases compared with age matched controls was highest in the temporal lobe.

Conclusions: Regional quantification of GFAP reveals that the glial response is most prominent in the temporal lobe in AD.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / metabolism*
  • Astrocytes / chemistry
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Frontal Lobe / chemistry
  • Glial Fibrillary Acidic Protein / analysis*
  • Humans
  • Occipital Lobe / chemistry
  • Parietal Lobe / chemistry
  • Temporal Lobe / chemistry


  • Glial Fibrillary Acidic Protein